Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
SummaryBackground Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of tanibirumab in patients… Expand
Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
- W. Lee, S. R. Shim, Seon Young Lee, J. S. Yoo, S. Cho
- Chemistry, Medicine
- Drug design, development and therapy
- 8 March 2018
Background VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial proliferation, permeability, and survival. Tanibirumab (TTAC-0001) is… Expand
ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA…
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
2522 Background: Tanibirumab is a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of Tanibirumab in… Expand
Management of Inguinal Hernia Recurrences (When Pain Is the Primary Symptom)
Recurrence after inguinal hernia repair occurs in 5 % patients, while chronic pain affects 10 % of patients. Chronic pain can be debilitating, and a multidisciplinary approach to management is often… Expand
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).
e13522Background: Treatment of recurrent GBM remains a challenge. The VEGF signal transduction pathway is upregulated in GBM. We evaluated Tanibirumab, a mAb to VEGFR2, in an open-label,… Expand
Double antibody address new way and use thereof
A scFv dual direction comprising a binding domain Tie-2 angiopoietin (Ang-2) fused through a linker to the N-terminus of the light chain of a scFv directed against the VEGFR2 region, said antibody… Expand
Direct observation of x-ray radiation-induced damage to SiO2/Si interface using multiwavelength room temperature photoluminescence
Higher failure rates have been observed for devices at or adjacent to areas that have been measured or inspected by in-line x-ray during front end of line process steps. The failures are thought to… Expand
420 Laparoscopic Low Anterior Resection With Transrectal Specimen Extraction and Intracorporeal Anastomosis